chrisvoncsefalvay/vaers-outcomes huggingface dataset:
arm has been hurting; arm has been difficult to move; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (arm has been hurting) and HYPOKINESIA (arm has been difficult to move) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031B21A and 027A21A) for COVID-19 vaccination.     Concurrent medical conditions included Arthritis. Concomitant products included LISINOPRIL, ATORVASTATIN, VITAMINS NOS, MAGNESIUM, ASCORBIC ACID (VITAMIN C ACID), VITAMIN B3 and CURCUMA LONGA (TURMERIC [CURCUMA LONGA]) for an unknown indication.   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Mar-2021, the patient experienced PAIN IN EXTREMITY (arm has been hurting) and HYPOKINESIA (arm has been difficult to move). At the time of the report, PAIN IN EXTREMITY (arm has been hurting) and HYPOKINESIA (arm has been difficult to move) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered PAIN IN EXTREMITY (arm has been hurting) to be not related. No further causality assessment was provided for HYPOKINESIA (arm has been difficult to move).    Additional concomitant medications include ginger powder. Treatment medication include hot shower.   Most recent FOLLOW-UP information incorporated above includes: On 17-May-2021: Follow-up information received on 17-May-2021, events were medically confirmed, relevant medical history was updated. Causality for the event arm pain was updated to not related.
Has localized rash and redness to site of injection. States is itchy and bumpy. Has been putting Benadryl cream on it to help decrease the itch.
About 48 hours after first dose, I felt fatigued, dizziness, headache, and feeling of vertigo. It is now about 1 week since vaccination and I still feel dizziness and vertigo, which I still feel continuously.
After receiving the booster dose he has continued feeling like hell and like he have been shot; congestion; no energy, tremendous weakness; sore throat; change in taste; temperature of 100.4; chills; headaches; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (After receiving the booster dose he has continued feeling like hell and like he have been shot), NASAL CONGESTION (congestion), ASTHENIA (no energy, tremendous weakness), OROPHARYNGEAL PAIN (sore throat) and TASTE DISORDER (change in taste) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011F21A, 016B21A and 027A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 13-Jan-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 13-Jan-2022, the patient experienced VACCINATION COMPLICATION (After receiving the booster dose he has continued feeling like hell and like he have been shot), NASAL CONGESTION (congestion), ASTHENIA (no energy, tremendous weakness), OROPHARYNGEAL PAIN (sore throat), TASTE DISORDER (change in taste), BODY TEMPERATURE INCREASED (temperature of 100.4), CHILLS (chills) and HEADACHE (headaches). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) at an unspecified dose and frequency. At the time of the report, VACCINATION COMPLICATION (After receiving the booster dose he has continued feeling like hell and like he have been shot), NASAL CONGESTION (congestion), ASTHENIA (no energy, tremendous weakness), OROPHARYNGEAL PAIN (sore throat), TASTE DISORDER (change in taste), BODY TEMPERATURE INCREASED (temperature of 100.4), CHILLS (chills) and HEADACHE (headaches) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 13-Jan-2022, Body temperature increased: temperature of 100.4 (High) temperature of 100.4. On an unknown date, Influenza virus test: negative (Negative) Negative. On an unknown date, SARS-CoV-2 antibody test: results pending test had no result yet..     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported. Patient was prescribed by antibiotics and steroids by his HCP.
This case was reported by a consumer via call center representative and described the occurrence of adverse reaction in a female patient who received SHINGRIX. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced adverse reaction. On an unknown date, the outcome of the adverse reaction was unknown. It was unknown if the reporter considered the adverse reaction to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The patient was concerned to received the scheduled 2nd dose of the SHINGRIX vaccine because, she had a reaction (not specified) to the 1st dose of SHINGRIX. The patient also expressed concern as she would not be able to donate the blood as the vaccine was listed as live vaccine by Food and Drug Administration.
Moderna vaccine was given to a 17 year old patient, no adverse reactions have been reported at this time, was discovered internally by billing team.
PATIENT RETURNED TO PHARMACY 3 DAYS AFTER RECEIVING BOTH FLU AND PNEUMONIA SHOTS IN THE LEFT ARM TO REPORT AN ADVERSE REACTION.  PT'S ARM WAS VISIBLY RED AND HAD AN EXTENSIVE RASH AT AND SURROUNDING SITES OF ADMINISTRATION.  PATIENT REPORTED THAT THE AREA IS AND HAS BEEN SWOLLEN.  SHE ALSO STATED SHE HAS HAD FLU-LIKE SYMPTOMS SINCE THE EVENING OF THE SHOTS AND STILL FEELS SICK.   PT WAS ADVISED TO TAKE ORAL BENADRYL AND TO PUT ICE ON THE AREA (SHE SAID HAS BEEN ICING IT).  SHE REQUESTED SOMETHING TOPICAL - TOPICAL BENADRYL CREAM OR HYDROCORTISONE WERE RECOMMENDED.
Initial cold and flu symptoms (When no cold or flu symptoms at all in the weeks leading up to vaccination, booster shot of CERVARIX for HPV prevention) Nausea (vomiting, twice on Sunday 26th August Extremely persistent high temperatures, up to 38.8 degrees celsius up to one week after the vaccination, healed only by medical intervention with visit to Doctor (who confirmed a very high heart rate) and taking of liquid panado syrup and medication to dry up water in ears and cold effects. No antibiotics given. Desire to sleep for bouts in the daytime, up to 2 hours at a time, in addition to night time sleep. Small spots on hands and face, disappeared after four days of vaccination. Loss of energy.
Body aches/headache/low fever/nauseous 8:00pm  April 7, 2021  through  10:00 pm April 8, 2021
Patient received varicella dose on 02/27/2019.  At the time patient was not aware she was pregnant.
Pfizer-BioN Tech COVID19 Vaccine EUA Injection site soreness in deltoid and shoulder region starting next day lasting roughly 24 hours.  No treatment other than Advil
Pt received Td lower left Deltoid, pt felt dizzy, lightheaded decreased BP. Observered x 30 minutes.
Normal side effects of fatique, aches but have been getting worse and worse chest congestion and wet coughing. Chest hurts.
Patient was airlifted to the hospital where she was diagnosed with a heart attack; Difficulty breathing; Numbness; Discomfort; Nausea; Vomiting; Burning/arm felt sore; This spontaneous case was reported by a consumer and describes the occurrence of MYOCARDIAL INFARCTION (Patient was airlifted to the hospital where she was diagnosed with a heart attack), DYSPNOEA (Difficulty breathing), HYPOAESTHESIA (Numbness), DISCOMFORT (Discomfort), NAUSEA (Nausea) and VOMITING (Vomiting) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 01003807772739901769) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Mar-2021, the patient experienced MYOCARDIAL INFARCTION (Patient was airlifted to the hospital where she was diagnosed with a heart attack) (seriousness criteria hospitalization and medically significant). On an unknown date, the patient experienced DYSPNOEA (Difficulty breathing) (seriousness criterion medically significant), HYPOAESTHESIA (Numbness) (seriousness criterion medically significant), DISCOMFORT (Discomfort) (seriousness criterion medically significant), NAUSEA (Nausea) (seriousness criterion medically significant), VOMITING (Vomiting) (seriousness criterion medically significant) and PAIN IN EXTREMITY (Burning/arm felt sore). At the time of the report, MYOCARDIAL INFARCTION (Patient was airlifted to the hospital where she was diagnosed with a heart attack), DYSPNOEA (Difficulty breathing), HYPOAESTHESIA (Numbness), DISCOMFORT (Discomfort), NAUSEA (Nausea), VOMITING (Vomiting) and PAIN IN EXTREMITY (Burning/arm felt sore) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  Treatment information was not provided.  The patient was discharged several days later.  Very limited information regarding this event/s has been provided at this time.  Further information has been requested.   This case was linked to MOD-2021-237455 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 28-Jun-2021: Non-significant follow-up added  to include Lot number; Sender's Comments: Very limited information regarding this event/s has been provided at this time.  Further information has been requested.
I had soreness in my left breast and in my shoulder, I went to my PCP and they advised to get a routine mammogram.  They saw a mass on the mammogram.  They sent my PCP a recommendation to get an ultrasound.  They concluded after the ultrasound that it was a cluster of lymph nodes.
Onset of pericarditis 6 days after 2nd Pfizer vaccine - with CRP elevation and EKG changes.  Symptomatically resolving after 1 week of treatment with ibuprofen.
Fever two days after injection. Starting 7/31/21 pain rash swelling at infection site nausea vomiting rash on stomach
Server headache (probable migraine), chills, muscle aches, orthostatic hypotension, blacked out
Information has been received from a licensed practical nurse referring to a patient of unknown age and gender. On 07-JUL-2016 a dose of improperly stored M-M-R II (lot# L027591, rHA, expiration date 23-JUL-2017) was given to the patient. No adverse effects reported. The temperature excursion was 48 degree Fahrenheit for 24 hours, data logger was used. There was no prior excursion. The temperature was back in range at the time of reporting. This is one of several reports received from the same source. Additional information is not expected as there is no consent to contact the physician.
When I got my second dose in Apr I had 103 fever for a a day and 102 to 100 for 2 more days. Took me a week to get back my normal self, i.e. when I could start playing sport again.  About 30 hours after my booster (3rd) shot, my fever peaked at 105.4 last night, and that's after 6 200 mg NSAIDS Advils + ice pack. And I was debating whether to call 911. It started about 8 hours after the shot and was between 100 and 103 thru until hour 26. Now it's about 53 hours after my shot, my fever is 101.  Is this a cytokine storm of some sort? Is this vaccine really for everyone? In my case, the cure seems to be worse than the pain.
headache; arm hurt; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache) and LIMB DISCOMFORT (arm hurt) in a 61-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2021, the patient experienced HEADACHE (headache) and LIMB DISCOMFORT (arm hurt). At the time of the report, HEADACHE (headache) and LIMB DISCOMFORT (arm hurt) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Patient scheduled to receive to vaccines at the pharmacy today (10/6/23) for Covid-19 Comirnaty and Flu vaccine. Patient had completed their form digitally prior to arriving to appointment today.  A second form was given to the patient to complete at time of arrival to their appointment. The patient had initially marked "Yes" to allergies and provided that they have an egg allergy on the digital form but did not include this on the recent written form completed today. The patient had marked "No" to allergies on the written form. Both copies of the forms were printed and taken to the vaccination room. At time of vaccination patient received Covid-19 Comirnaty vaccine and Fluarix Quadrivalent in their left deltoid. After administering both vaccines patient mentioned that they called someone(unknown) prior to appointment and that person had informed them that all of the new flu vaccines do not have egg in them. The patient was informed by the administering Pharmacist that this is not true and that the Fluarix vaccine should not be used with an egg allergy and that the patient should have received Flucelvax which is cell-based and suitable for patients with an egg allergy. Patient then mentioned that they have an egg allergy and that they tend to have a rash and shortness of breath when administered eggs.  Patient was then offered EMS service but patient declined. Patient then started to feel rashy and shaky. Patient informed that they are able to drive 1.9 miles to a nearby urgent care and would call later today to update the pharmacy manager on their status/health.
Started getting more frequent PVC's (Premature ventricular contractions) on a daily basis lasting for hours; This is a spontaneous report from a contactable consumer (patient). A 55-years-old non pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot number: not reported), via an unspecified route of administration, administered in Left arm on 05Apr2021 at 01:00 PM as a single dose for covid-19 immunisation at hospital. The patient medical history was not reported. Concomitant medication included metoprolol and diuretic. Patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot number: EN6208), via an unspecified route of administration, administered in Left arm on an unknown date as a single dose for covid-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Patient did not receive any other vaccine in four weeks of vaccination. On 19Apr2021, after the 2nd dose the patient started getting more frequent PVCs (premature ventricular contractions) on a daily basis lasting for hours. Treatment with metoprolol increased to 50 mg 2 times per day for the event. The event resulted in Emergency room/department or urgent care. The outcome of the event was unknown.  Information on the lot/batch number has been requested.
Generalized maculopapular rash with onset around trunk and more generalized spread. Rash developed 2 days after vaccination. No difficulty breathing. No vomiting. No fever. No other sick symptoms at time of clinic evaluation for the rash. Rash appearing non-pruritic.  Rash appearing to slowly resolve spontaneously since onset.
Information has been received from a physician assistant concerning an approximately 12 months year old female who unspecified date was vaccinated with a dose of VARIVAX (Merck) (Lot#Unknown). The medical assistant stated that "the patient broke out in rash about five days after she was receiving dose of VARIVAX (Merck). At the time of the report the patient's outcome was recovered. Additional information has been requested.
pregnancy; This spontaneous prospective pregnancy case was reported by a nurse and describes the occurrence of EXPOSURE DURING PREGNANCY (pregnancy) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010M20A and 013L20A) for COVID-19 vaccination.     Concomitant products included PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE], PARACETAMOL (TYLENOL), LEVOCETIRIZINE DIHYDROCHLORIDE (XYZAL), OMEPRAZOLE and ACETYLSALICYLIC ACID (ASPIRIN 81) for an unknown indication.   On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 05-Sep-2020 and the estimated date of delivery was 12-Jun-2021. On 20-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  nineteenth week of the pregnancy.  On 20-Jan-2021, EXPOSURE DURING PREGNANCY (pregnancy) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was reported.   Most recent FOLLOW-UP information incorporated above includes: On 26-May-2021: Updated reporter Information, pregnancy details, suspect product details and concomitant medications.
LESS ENERGY; FEELING LIGHT HEADED OFF AND ON; PRESSURE IN HEAD OR FEELING OF PRESSURE; NUMBNESS OF THE TONGUE; FELT THE CONDITION (HEART VALVE DISORDER) WORSENED SINCE RECEIVING THE VACCINE; This spontaneous report received from a patient concerned a 56 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included hx heart valve disorder. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A, expiry: 07-AUG-2021) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported.  On APR-2021, the subject experienced felt the condition (heart valve disorder) worsened since receiving the vaccine. On 08-APR-2021, the subject experienced numbness of the tongue. Treatment medications included: diphenhydramine hydrochloride. On 18-APR-2021, the subject experienced feeling light headed off and on. On 18-APR-2021, the subject experienced pressure in head or feeling of pressure. On 18-MAY-2021, the subject experienced less energy. Laboratory data (dates unspecified) included: Blood test (NR: not provided) Unknown, Carotid angiogram (NR: not provided) Unknown, Electrocardiogram (NR: not provided) Unknown, and Magnetic resonance imaging (NR: not provided) Unknown. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from numbness of the tongue on 08-JUL-2021, had not recovered from feeling light headed off and on, and the outcome of pressure in head or feeling of pressure, less energy and felt the condition (heart valve disorder) worsened since receiving the vaccine was not reported. This report was non-serious.
vaccination site warmth; vaccination site irritation; injection site redness; vaccination site tenderness; vaccination site swelling; This is a spontaneous report received from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via unspecified route of administration on 20Mar2021 (at the age of 34-years-old) in right arm for COVID-19 immunisation. The medical history and concomitant medications were not reported. The patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198) via unspecified route of administration on 27Feb2021 in right arm for COVID-19 immunisation. The patient did not receive any other vaccine within 4 weeks of COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient was not tested for COVID-19. On 20March2021 (day 1), the patient experienced some tenderness (vaccination site tenderness) and a small swelling, a bump of approximately the size of a quarter at the site injection (vaccination site swelling). There was no irritation or redness. On 21Mar2021 (day 2), the bump had softened and tenderness was replaced with slight irritation and redness of approximately 1.5 inches in diameter at the site of injection. On 22Mar2021 (day 3), the redness had grown to 3 inches in diameter with added irritation and noticeably warm to the touch (vaccination site warmth). The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of vaccination site tenderness, vaccination site swelling, vaccination site irritation, injection site redness and vaccination site warmth was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Patient states he had a pfizer covid vaccine in september 2021. In december 2021 he developed heat racing, increased blood pressure, right elbow/hand, bilateral shoulder and right calf numbness, decreased appetite, increased urination. Recommendations from his PCP were weight loss and exercise.
This case was reported by a consumer via call center representative and described the occurrence of neuropathy peripheral in a male patient who received SHINGRIX for prophylaxis. The patient's past medical history included numbness in feet (for years). On 3rd August 2018, the patient received the 2nd dose of SHINGRIX. On 3rd August 2018, less than a day after receiving SHINGRIX, the patient experienced neuropathy peripheral (serious criteria GSK medically significant) and foot pain. On an unknown date, the outcome of the neuropathy peripheral and foot pain were unknown. It was unknown if the reporter considered the neuropathy peripheral and foot pain to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient reported that he received SHINGRIX and experienced severe neuropathy in feet. The patient also reported that he never had pain before though he had numbness in feet for years. The pain kept the patient up virtually all night long. The patient wondered if this event would resolve in a day or two or if this was totally unrelated to the vaccine.
Swelling on left leg, rash on head and face hive all over the body, and fever, and blisters around injection sight.
Horrible sore shoulder since 1800 on 9/20. Couldn't sleep on it, pain relieveers don't help. Can't even abduct it past 30 degrees or adduct it past zero degrees. Also, left arm was tingly today